ECF vs. BBH, NQP, MUA, HRZN, MYN, TYG, KTF, HQL, MCI, and SOR
Should you be buying Ellsworth Growth and Income Fund stock or one of its competitors? The main competitors of Ellsworth Growth and Income Fund include VanEck Biotech ETF (BBH), Nuveen Pennsylvania Quality Municipal Income Fund (NQP), BlackRock MuniAssets Fund (MUA), Horizon Technology Finance (HRZN), BlackRock MuniYield New York Quality Fund (MYN), Tortoise Energy Infrastructure (TYG), DWS Municipal Income Trust (KTF), Abrdn Life Sciences Investors (HQL), Barings Corporate Investors (MCI), and Source Capital (SOR). These companies are all part of the "investment offices, not elsewhere classified" industry.
VanEck Biotech ETF (NASDAQ:BBH) and Ellsworth Growth and Income Fund (NYSE:ECF) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.
Given Ellsworth Growth and Income Fund's higher possible upside, equities research analysts plainly believe VanEck Biotech ETF is more favorable than Ellsworth Growth and Income Fund.
32.1% of VanEck Biotech ETF shares are owned by institutional investors. Comparatively, 35.9% of Ellsworth Growth and Income Fund shares are owned by institutional investors. 0.5% of Ellsworth Growth and Income Fund shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
VanEck Biotech ETF pays an annual dividend of $0.71 per share and has a dividend yield of 0.4%. Ellsworth Growth and Income Fund pays an annual dividend of $0.52 per share and has a dividend yield of 6.4%. Ellsworth Growth and Income Fund has increased its dividend for 1 consecutive years. Ellsworth Growth and Income Fund is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
VanEck Biotech ETF received 38 more outperform votes than Ellsworth Growth and Income Fund when rated by MarketBeat users.
VanEck Biotech ETF has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Ellsworth Growth and Income Fund has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
In the previous week, VanEck Biotech ETF had 3 more articles in the media than Ellsworth Growth and Income Fund. MarketBeat recorded 3 mentions for VanEck Biotech ETF and 0 mentions for Ellsworth Growth and Income Fund. VanEck Biotech ETF's average media sentiment score of 0.68 beat Ellsworth Growth and Income Fund's score of 0.62 indicating that Ellsworth Growth and Income Fund is being referred to more favorably in the news media.
Summary
Ellsworth Growth and Income Fund beats VanEck Biotech ETF on 6 of the 10 factors compared between the two stocks.
Get Ellsworth Growth and Income Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for ECF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ECF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ellsworth Growth and Income Fund Competitors List
Related Companies and Tools
